Date:5/3/2012

their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K on March 2, 2012 under the heading "Risk Factors."DURECT CORPORATIONSTATEMENTS OF COMPREHENSIVE INCOME (LOSS) (in thousands, except per share amounts)(Unaudited)Three months ended March 31, 20122011Collaborative research and development and other revenue

$38,328$ 5,512Product revenue, net

2,8573,092Total revenues

41,1858,604Operating expenses:Cost of product revenues

1,4611,401Research and development

5,6349,880Selling, general and administrative

3,2803,716Total operating expenses

10,37514,997Income (loss) from operations

30,810(6,393)Other income (expense):Interest and other income

2140Interest expense

(2)(4)Net other income

1936Net Income (loss)

$30,829$(6,357)Net income (loss) per shareBasic $ 0.35$ (0.07)Diluted$ 0.35$ (0.07)Weighted-average shares used in computing net income (loss) per shareBasic 87,54787,270Diluted87,56887,270Total comprehensive income (loss)

$30,826$(6,343) DURECT CORPORATIONCONDENSED BALANCE SHEETS (in thousands)As ofAs ofMarc
'/>"/>

SOURCE DURECT Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
3. DURECT to Participate in Upcoming Healthcare Conferences
4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
10. DURECT to Present at the Jefferies Healthcare Conference
11. DURECT Announces Resignation of Chief Medical Officer